GlassScriptPhysician profile
Shannon Reid
NPI 1336783455
$1,979.90
in general payments reported to CMS, 2019-2025
29 companies · $227 in 2025
The $227 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,080 · 2022: $459 · 2023: $130 · 2024: $83.69 · 2025: $227.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $441.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $440.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $282.04 | 2021-2022 | |
| Incyte Corporation | $236.63 | 2021 | |
| Amgen INC. | $174.80 | 2021-2022 | |
| Janssen Biotech, INC. | $145.64 | 2022-2023 | Darzalex, Imbruvica |
| Otsuka America Pharmaceutical, INC. | $142.88 | 2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $114.59 | 2021-2023 | Lokelma |
| Ucb, INC. | $96.85 | 2024-2025 | Briviact, Nayzilam |
| Daiichi Sankyo INC. | $82.88 | 2021 | |
| Amag Pharmaceuticals, INC. | $64.58 | 2021-2022 | |
| Glaxosmithkline, LLC. | $60.22 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $58.87 | 2021 | |
| Neurocrine Biosciences, INC. | $57.58 | 2024-2025 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $57.41 | 2021 | |
| Genzyme Corporation | $55.23 | 2021-2022 | |
| Urovant Sciences INC | $52.04 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $49.39 | 2023 | Gemtesa |
| Novartis Pharmaceuticals Corporation | $42.95 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $41.58 | 2021 | |
| Morphosys, US INC. | $18.50 | 2022 | |
| Helsinn Therapeutics (U.S.), INC. | $18.27 | 2021 | |
| Pfizer INC. | $17.90 | 2021 | |
| Alexion Pharmaceuticals, INC. | $15.35 | 2021 | |
| Merck Sharp & Dohme LLC | $15.27 | 2022 | |
| Celgene Corporation | $14.82 | 2021 | |
| Lilly USA, LLC | $13.76 | 2021 | |
| Jazz Pharmaceuticals INC. | $13.54 | 2021 | |
| Alpha Cognition USA, INC. | $13.34 | 2025 | Zunveyl |
| Acadia Pharmaceuticals INC | $11.71 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $11.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shannon Reid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.